Seqens Seqens

X

Find Radio Compass News for Velpatasvir

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

0

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

https://seekingalpha.com/news/3705521-fda-approves-new-formulation-gileads-epclusa-for-children-ages-3-and-older-with-hcv

Jonathan.M SEEKING ALPHA
10 Jun 2021

http://www.pharmatimes.com/news/fda_oks_gileads_paediatric_hep_c_drug_1329622

Anna Smith PHARMATIMES
20 Mar 2020

https://www.businesswire.com/news/home/20200319005700/en

BUSINESSWIRE
19 Mar 2020

https://www.fiercepharma.com/marketing/gilead-airs-first-hep-c-epclusa-campaign-even-as-its-own-generics-way

Beth S Bulik FIERCE PHARMA
05 Feb 2019

https://www.gilead.com/news-and-press/press-room/press-releases/2019/1/japans-ministry-of-health-labour-and-welfare-approves-gileads-epclusa-sofosbuvirvelpatasvir

PRESS RELEASE
08 Jan 2019

https://www.fiercepharma.com/marketing/abbvie-highlights-mavyret-s-8-week-advantage-new-ad-campaign-as-it-continues-its-hep-c

Beth S Bulik FIERCE PHARMA
13 Dec 2018

https://www.biospace.com/article/hookipa-biotech-and-gilead-ink-deal-to-develop-hiv-and-hepatitis-b-therapies/

Mark Terry BIOSPACE
05 Jun 2018
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY